SCHEMBL196971

SCHEMBL196971

CCOC(=O)C(C)N(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
LMNA P02545 2/20 0.42
HSD17B10 Q99714 1/20 0.42
ALOX15 P16050 1/20 0.40
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
SOAT1 P35610 1/20 0.40
CHRNB2 P17787 6/20 0.38
CHRNA4 P43681 6/20 0.38
CHRNB4 P30926 4/20 0.38
CHRNA3 P32297 3/20 0.38
TRPA1 O75762 1/20 0.37
HTT P42858 1/20 0.37
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL196972 1.00 ALDH1A1 (0.43) ALDH1A1CA12CA1CA2CA9
Sulfuric Acid SCHEMBL28347706 0.91 CA12 (0.37) ALDH1A1CA12CA1CA2CA9
Dodecanol SCHEMBL5667394 0.83 LMNA (0.45) ALDH1A1LMNAHSD17B10MAPT
SCHEMBL7094569 0.82 ALDH1A1 (0.46) ALDH1A1CA12CA1CA2CA9
SCHEMBL25028435 0.81 ALDH1A1 (0.40) ALDH1A1CA12CA1CA2CA9
SCHEMBL15802692 0.81 CHRNB2 (0.41) ALDH1A1LMNAHSD17B10CHRNB2CHRNA4
SCHEMBL13018204 0.81 ALDH1A1 (0.44) ALDH1A1CA12CA1CA2CA9
SCHEMBL22899056 0.81 ALDH1A1 (0.40) ALDH1A1CA12CA1CA2CA9
SCHEMBL19189532 0.81 ALDH1A1 (0.40) ALDH1A1CA12CA1CA2CA9
SCHEMBL197598 0.81 CHRNB2 (0.41) ALDH1A1LMNAHSD17B10CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1428816-B1 Method for the manufacture of dodecyl 2-(n,n-dimethylamino)-propionate NEXMED HOLDINGS INC (US) 2012-09-05 EP claimed
EP-1428816-A1 Method for the manufacture of dodecyl 2-(n,n-dimethylamino)-propionate Nexmed Holdings, Inc. (US) 2004-06-16 EP claimed
EP-1097126-A4 CRYSTALLINE SALTS OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE NEXMED HOLDINGS INC (US) 2002-08-28 EP claimed
EP-1097126-A1 CRYSTALLINE SALTS OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE Nexmed Holdings, Inc. (US) 2001-05-09 EP claimed
WO-2000069809-A1 CRYSTALLINE SALTS OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE NEXMED HOLDINGS, INC. (US) 2000-11-23 WO claimed
US-11246932-B2 Prostaglandin compositions and methods for the treatment of vasospasm NEXMED HOLDINGS, INC. (US) 2022-02-15 US disclosed
WO-2020221826-A1 NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2020-11-05 WO disclosed
WO-2020221816-A1 NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2020-11-05 WO disclosed
US-10766882-B2 1,2-naphthoquinone based derivative and method of preparing the same YUNGJIN PHARM CO., LTD. (KR) 2020-09-08 US disclosed
EP-2646015-B1 ACTIVE ENANTIOMER OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE FERRING INT CENTER SA (CH) 2020-04-22 EP disclosed
US-20190076529-A1 PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM NEXMED HOLDINGS, INC. (US) 2019-03-14 US disclosed
US-9975883-B2 1,2-naphthoquinone based derivative and method of preparing the same YUNGJIN PHARM. CO., LTD. (KR) 2018-05-22 US disclosed
EP-0643128-B1 Aqueous fabric softener composition, novel quaternary ammonium salt, and process for the preparation of said salt KAO CORP (JP) 1999-03-10 EP disclosed
US-5580481-A Aqueous fabric softener composition, novel quaternary ammonium salt, and process for the preparation of said salt KAO CORPORATION (JP) 1996-12-03 US disclosed
US-5476597-A Storage stability, elasticity KAO CORPORATION (JP) 1995-12-19 US disclosed
EP-0643128-A1 Aqueous fabric softener composition, novel quaternary ammonium salt, and process for the preparation of said salt Kao Corporation (JP) 1995-03-15 EP disclosed
EP-0014997-B1 4-ARYLOXY- AND 4-ARYLTHIO-3-PHENYLPIPERIDINE DERIVATIVES, A PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HOECHST AKTIENGESELLSCHAFT (DE) 1983-07-20 EP disclosed
EP-0020018-B1 CHROMAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BEECHAM GROUP PLC (GB) 1983-06-01 EP disclosed
US-4303656-A ANOREXIC AGENTS BEECHAM GROUP LIMITED (GB) 1981-12-01 US disclosed
EP-0020018-A1 Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1980-12-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10766882-B2 1,2-naphthoquinone based derivative and method of preparing the same CYP2S1, GYS2, SLC5A1 ALDH1A1 688/4885CA12 4298/4885CA1 3086/4885
US-20190076529-A1 PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM PTGIS, PTGIR, PGF ALDH1A1 2025/4885CA12 3395/4885CA1 2360/4885
US-11246932-B2 Prostaglandin compositions and methods for the treatment of vasospasm PTGIS, PTGIR, PGF ALDH1A1 2025/4885CA12 3395/4885CA1 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.